Skip to main content
. 2020 Jul 7;12(1):1779974. doi: 10.1080/19420862.2020.1779974

Figure 7.

Figure 7.

Hinge mutations do not affect antigen, FcRn or FcγRIIIa binding in vitro. (a) Antigen binding of the IgG4 mAbs with the indicated hinge mutations were compared to the unmodified IgG4 in an ELISA assay. An isotype control demonstrated no binding up to 5000 nM (not shown). Data represent the mean ± SD of duplicate experiments. (b) FcRn and (c) FcγRIIIa binding for the IgG4 s with hinge mutations were compared to the unmodified IgG4 in AlphaLISA assays. Rituximab was run as a known positive control in the FcγRIIIa AlphaLISA. Data represent the mean ± SD of duplicate independent experiments.